美国肾移植可及性性别差异趋势:全国队列研究
该回顾性队列研究基于美国肾脏数据系统2.3百万成人,分析1997-2020年启动肾脏替代治疗者中性别与移植可及性的关联。结果显示等待名单登记性别差异改善但仍显著,活体供肾移植性别差异扩大,等待名单患者 deceased 供肾移植性别差异反转。
要点
- 等待名单登记性别差异从1997-2000年aHR 0.81缩小至2017-2020年0.86
- 活体供肾移植性别差异扩大:aHR从0.89降至0.79
- deceased供肾移植性别差异反转:aHR从0.92升至1.16
核心结论
- 自1997年以来等待名单登记性别差异改善但仍显著,老年和糖尿病相关肾衰竭女性差异最大。
- 活体供肾移植性别差异扩大, deceased供肾移植性别差异反转,需进一步研究。
研究设计与样本
- 回顾性队列研究,纳入美国肾脏数据系统2.3百万18-79岁1997-2020年启动肾脏替代治疗的成人。
- 采用多变量病因特异性风险模型分析性别与等待名单登记、活体供肾移植和 deceased供肾移植的关联。
主要发现
- 等待名单登记:1997-2000年男性vs女性aHR 0.81(95%CI 0.79-0.83),2017-2020年aHR 0.86(95%CI 0.85-0.87)。
- 活体供肾移植:1997-2000年aHR 0.89(95%CI 0.85-0.93),2017-2020年aHR 0.79(95%CI 0.76-0.82)。
- deceased供肾移植:1997-2000年aHR 0.92(95%CI 0.89-0.95),2017-2020年aHR 1.16(95%CI 1.14-1.19)。
- 2017-2020年糖尿病女性等待名单登记和活体供肾移植性别差异分别为27%和37%,60-79岁女性分别为24%和34%。
临床怎么用
- 临床应关注老年和糖尿病相关肾衰竭女性等待名单登记和活体供肾移植的性别差异。
- 需针对性别差异设计政策和干预措施以改善移植公平性。
局限性
- 存在残余混杂。
- 未知移植的真实医学资格。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Women with kidney failure have reduced access to kidney transplantation compared with men. We examined trends in sex inequities in access to transplantation over time. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 2.3 million adults identified within the US Renal Data System, aged 18-79 years, who initiated kidney replacement therapy (KRT) between 1997 and 2020. EXPOSURE: Era of KRT (1997-2000, 2001-2004, 2005-2008, 2009-2012, 2013-2016, or 2017-2020), sex (male or female). OUTCOME: Placement onto the kidney transplant waitlist, or living-donor kidney transplant (LDKT) among all individuals initiating KRT, and deceased donor kidney transplantation (DDKT) among patients on the waitlist. ANALYTICAL APPROACH: Multivariable cause-specific hazard models to analyze the association between sex and placement onto the waitlist, LDKT, and DDKT, by era, overall, and by categories of age, race, and cause of kidney failure. RESULTS: Sex inequities in waitlisting became less pronounced over time. During 1997-2000 the adjusted HR comparing men with women was 0.81 (95% CI, 0.79-0.83); by 2017-2020, it had narrowed to 0.86 (95% CI, 0.85-0.87). For the outcome of LDKT, during 1997-2000, the adjusted HR comparing men with women was 0.89 (95% CI, 0.85-0.93) and by 2017-2020 had widened to 0.79 (95% CI, 0.76-0.82). For the outcome of DDKT, during 1997-2000, the adjusted HR comparing men with women was 0.92 (95% CI, 0.89-0.95) and by 2017-2020 had widened to 1.16 (95% CI, 1.14-1.19). Sex inequities in waitlisting and LDKT were greatest in women (vs men) with diabetes (27% and 37%, respectively, in 2017-2020) and older adults 60-79 years (24% and 34%, respectively, in 2017-2020), but were broadly similar across race groups. LIMITATIONS: Residual confounding; unknown true medical eligibility for transplant. CONCLUSIONS: Since 1997, sex inequities in waitlisting have improved but remain significant, especially for women who are older and who have diabetes-attributed kidney failure. Worsening sex inequities in LDKT among women and DDKT among waitlisted men warrant further study. PLAIN-LANGUAGE SUMMARY: Women with kidney failure have historically had poorer access to kidney transplantation than men. The goal of the current study was to see whether access to transplantation, defined as placement onto the transplant waitlist or living (LDKT) or deceased donor kidney transplantation (DDKT), has changed over time using national registry data from>2.3 million adults initiating kidney replacement therapy in the United States. Overall, this study showed that since 1997 sex inequities in placement on the transplant waitlist have improved but remain significant, especially for women who are older or have diabetes. Unfortunately, sex inequities in LDKT favoring men have worsened over time while declines in DDKT appear to have impacted men more than women. These findings have implications for the design of policies and interventions to improve transplant equity.
引用
- Harding JL, Hu C, Pastan SO, et al. Trends in Sex Disparities in Access to Kidney Transplantation: A Nationwide US Cohort Study. Am J Kidney Dis. 2025. PMID: 40023214. doi:10.1053/j.ajkd.2024.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。